AbCellera Biologics (8QQ) Price & Analysis

7 Followers

8QQ Stock Chart & Stats

€10.34

€0.02(0.40%)

At close: Jul 24 4:00 PM EDT

€10.34

€0.02(0.40%)

Day’s Range― - ―

52-Week Range€2.49 - €10.78

Previous CloseN/A

Volume130.00

Average Volume (3M)1.29K

Market Cap

€3.08B

Enterprise Value€1.97K

Total Cash (Recent Filing)€540.10M

Total Debt (Recent Filing)€135.62M

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Nov 10, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding324,047,360

10 Day Avg. Volume690

30 Day Avg. Volume1,288

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)1.06

Price to Sales (P/S)13.60

P/FCF Ratio-5.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€14.78

Price Target Upside42.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.57

Revenue Forecast (FY)€21.69M

Bulls Say, Bears Say

Bulls Say

Strong Liquidity RunwaySubstantial cash, government funding and at least three years of planned pipeline support reduce near-term financing risk. This gives AbCellera flexibility to fund clinical programs and platform investment while pursuing partnerships.

Strategic Partnership TractionPartnerships validate AbCellera’s T-cell engager capabilities and provide non-dilutive funding, external development support and potential royalties. They also broaden commercial reach and create multiple opportunities for downstream economics.

Integrated Antibody PlatformAn integrated platform can improve control over antibody discovery and early development, supporting repeat collaborations and faster candidate progression. Its breadth may strengthen AbCellera’s role across more stages of the biologics value chain.

Bears Say

Declining Revenue And Deep LossesFalling revenue alongside very large operating losses shows that the current cost base is not supported by recurring business activity. Sustained losses could weaken capital efficiency and increase dependence on financing, milestones or successful pipeline outcomes.

Negative Cash GenerationPersistent cash outflows indicate that operations and internal development currently consume capital rather than generate it. Although liquidity is strong, continued burn could reduce financial flexibility over time if partnerships or clinical programs do not deliver.

Clinical Execution And Revenue Concentration RiskPipeline value depends on uncertain clinical efficacy and timely execution, while limited recurring or product revenue leaves results reliant on collaborations and milestones. Failed studies or delays could therefore affect both funding visibility and long-term growth.

AbCellera Biologics News

AbCellera rises 17.0%

AbCellera (ABCL) is up 17.0%, or $1.80 to $12.41. Published first on TheFly – the ultimate source for...

17d ago

ABCL

AbCellera rises 10.7%

AbCellera (ABCL) is up 10.7%, or $1.13 to $11.74. Published first on TheFly – the ultimate source for...

17d ago

ABCL

AbCellera Biologics call volume above normal and directionally bullish

Bullish option flow detected in AbCellera (ABCL) Biologics with 17,987 calls trading, 2x expected, and implied vol increasing...

23d ago

ABCL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Tradr 2X Short SNDK...

24d ago

YSS

ABCL

AbCellera 17.4M share Secondary priced at $9.75

Jefferies, JPMorgan, Cantor Fitzgerald, UBS and BMO Capital acted as joint book running managers for the offering. Published...

25d ago

ABCL

AbCellera Biologics call volume above normal and directionally bullish

Bullish option flow detected in AbCellera (ABCL) Biologics with 9,297 calls trading, 2x expected, and implied vol increasing...

26d ago

ABCL

AbCellera Biologics Announces Oversubscribed $200 Million Offering

The latest announcement is out from AbCellera Biologics ( ($ABCL) ). On August 12, 2026, AbCellera Biologics Inc....

28d ago

ABCL

AbCellera announces $200M common stock, warrants offering

AbCellera (ABCL) Biologics announced that it has commenced an underwritten public offering of $200M of its common shares...

1M ago

ABCL

AbCellera price target raised to $30 from $12 at Truist

Truist raised the firm’s price target on AbCellera (ABCL) to $30 from $12 and keeps a Buy rating...

1M ago

ABCL

AbCellera Price Target Raised to $15 on Best-in-Class ABCL635 Phase 2 Data and Strategic Pipeline Momentum

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on AbCellera Biologics, with...

1M ago

ABCL

AbCellera price target raised to $25 from $13 at JonesResearch

JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on AbCellera (ABCL) to $25 from $13 and keeps...

1M ago

ABCL

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

AbCellera (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating...

1M ago

ABCL

AbCellera Earnings Call Balances Cash Strength With Risk

Abcellera Biologics, Inc. (($ABCL)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

ABCL

AbCellera to Report Phase 2 Menopause Therapy Data

AbCellera Biologics ( ($ABCL) ) has provided an update. On August 7, 2026, AbCellera announced it will release...

1M ago

ABCL

8QQ FAQ

What was AbCellera Biologics’s price range in the past 12 months?

AbCellera Biologics lowest stock price was €2.49 and its highest was €10.78 in the past 12 months.

What is AbCellera Biologics’s market cap?

AbCellera Biologics’s market cap is €3.08B.

When is AbCellera Biologics’s upcoming earnings report date?

AbCellera Biologics’s upcoming earnings report date is Nov 10, 2026 which is in 60 days.

How were AbCellera Biologics’s earnings last quarter?

AbCellera Biologics released its earnings results on Aug 05, 2026. The company reported -€0.155 earnings per share for the quarter, missing the consensus estimate of -€0.141 by -€0.014.

Is AbCellera Biologics overvalued?

According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AbCellera Biologics pay dividends?

AbCellera Biologics does not currently pay dividends.

What is AbCellera Biologics’s EPS estimate?

AbCellera Biologics’s EPS estimate is -0.15.

How many shares outstanding does AbCellera Biologics have?

AbCellera Biologics has 324,047,360 shares outstanding.

What happened to AbCellera Biologics’s price movement after its last earnings report?

AbCellera Biologics reported an EPS of -€0.155 in its last earnings report, missing expectations of -€0.141. Following the earnings report the stock price went up 4.523%.

Which hedge fund is a major shareholder of AbCellera Biologics?

Currently, no hedge funds are holding shares in DE:8QQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AbCellera Biologics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-6.74%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

AbCellera Biologics

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

AbCellera Biologics (8QQ) Earnings & Revenues

Historic Earnings Reports

8QQ Company Deck

8QQ Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys a cautiously optimistic outlook: the company is well capitalized with substantial upfront partnership cash, large potential deal value, and multiple near-term clinical catalysts (notably ABCL635 topline readout and ABCL575 Phase I readout). Those positives are tempered by a sharp year-over-year revenue decline (~-76.5%), a wider net loss (+57.1%), increased R&D spend, and remaining scientific and placebo-related risks for the lead program. On balance, the strong liquidity position and strategic partnerships alongside clear near-term catalysts outweigh the financial pressures and programmatic risks in the short term.View all DE:8QQ earnings summaries

8QQ Revenue Breakdown

93.51% Research fees

3.94% Royalty revenue

2.55% Milestone payments

8QQ Stock 12 Month Forecast

Average Price Target

€14.78

▲(42.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","26":"€26","7.25":"€7.25","13.5":"€13.5","19.75":"€19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25.8333183,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€25.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.782398805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€14.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.74999549,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.76,10.9964091,12.232818199999999,13.4692273,14.7056364,15.942045499999999,17.1784546,18.414863699999998,19.651272799999997,20.887681899999997,22.124090999999996,23.360500099999996,24.5969092,{"y":25.8333183,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.76,10.146338369615384,10.53267673923077,10.919015108846153,11.305353478461537,11.691691848076923,12.078030217692307,12.464368587307693,12.850706956923077,13.23704532653846,13.623383696153846,14.00972206576923,14.396060435384616,{"y":14.782398805,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.76,9.605384268461538,9.450768536923077,9.296152805384615,9.141537073846154,8.986921342307692,8.83230561076923,8.677689879230769,8.523074147692308,8.368458416153846,8.213842684615384,8.059226953076923,7.904611221538461,{"y":7.74999549,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.591,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.379,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.632,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.104,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.908,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.029,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.245,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >